title: Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomy.
abstract: OBJECTIVE
  To examine the effect of postoperative radiotherapy (RT) plus 2-yr androgen suppression (AS) on quality of life (QOL) in patients with pathologic T3 or positive resection margins after radical prostatectomy (RP).
  
  
  METHODS
  Seventy-eight patients underwent postoperative RT followed by 2-yr AS, in a phase 2 study, between 1998 and 2002. Median age was 61 yr at the time of RP. QOL was prospectively assessed with the European Organization for Research and Treatment of Cancer (EORTC) QOL Questionnaire 30-item version 3.0 with the added prostate cancer-specific module at baseline and predefined follow-up visits.
  
  
  RESULTS
  Patients experienced a significant increase in bowel dysfunction score (22%) by the end of RT, which would be considered a major change in QOL. This bowel dysfunction resolved after RT and showed no difference from baseline in the subsequent 2-yr AS period. A similar, but less pronounced, pattern of change occurred for the diarrhea domain. Urinary dysfunction score also increased at the end of RT by 6.6%, considered a clinically minor change in QOL. It then returned to baseline in the post-RT period. The cohort had poor erectile function at baseline; thus, it was difficult to assess any further decline in this domain brought on by RT or AS. In the remaining QOL domains, a change of minor or moderate clinical significance was observed at occasional time points for global health status, fatigue, pain, and insomnia.
  
  
  CONCLUSIONS
  Postoperative RT plus 2-yr AS after RP did not result in any major, persistent, adverse effect on QOL.
authors.affiliation: Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA. choo.c@mayo.edu
authors.forename: Richard
authors.initials: R
authors.lastname: Choo
authors.forename: Andrew
authors.initials: A
authors.lastname: Pearce
authors.forename: Cyril
authors.initials: C
authors.lastname: Danjoux
authors.forename: Gerard
authors.initials: G
authors.lastname: Morton
authors.forename: Gerrit
authors.initials: G
authors.lastname: Deboer
authors.forename: Ewa
authors.initials: E
authors.lastname: Szumacher
authors.forename: Andrew
authors.initials: A
authors.lastname: Loblaw
authors.forename: Patrick
authors.initials: P
authors.lastname: Cheung
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000503:physiopathology / Q000523:psychology* / Q000628:therapy; D011788:Quality of Life
chemical_list: D000726:Androgen Antagonists